

**Suppl. 1:** Clinicopathological parameters of the ADC patients included in the analysis of somatic mtDNA mutations

Patient	Sex	Age	pTNM	Approach
1	w	66	pT4, pN0 (0/25), Mx	Determination of somatic mitochondrial mutations
2	m	66	pT2, pN0 (0/24), Mx	
3	m	66	pT2, pN0(0/19), Mx,	
4	w	67	pT2, pN1 (1/19), Mx	
5	m	56	pT2, pN1 (6/46), Mx	
6	w	80	pT2-, pN0 (0/21), Mx	
7	w	66	pT2, pN0 (0/20), Mx	
8	w	69	pT4, pN2 (5/20), Mx	
9	m	75	pT2, pN0 (0/25), Mx	
10	m	56	pT2a, pN2 (4/38), pM1a(PLE)	
11	m	74	pT2b, pN1 (4/34), Mx	
12	w	76	pT1a, pN0(0/9), Mx	
13	w	49	pT4, pN2 (15/25), Mx	
14	w	69	pT2a, pN0 (0/28), Mx	
15	m	69	pT2a, pN0 (0/25), Mx	
16	w	73	pT1b, pNx, Mx	
17	w	69	pT2a, pN0 (0/48), Mx	
18	w	73	pT1b, pN0 (0/32), Mx	
19	m	63	pT2, pN0 (0/9), Mx	
20	w	57	pT2a, pN0 (0/26), Mx	
21	w	75	pT3, pN1 (1/31), Mx	
22	m	51	pT2a, pN1 (7/39), Mx	
23	w	60	pT2a, pN2 (3/16), Mx	
24	w	59	pT2a, pN0 (0/26), Mx	
25	w	68	pT2a, pN0 (0/19), Mx	
26	m	60	pT2b, pN1 (4/38), Mx	
I	m	51	pT2a, pN0 (0/21), Mx	Determination of the spatial distribution of mtDNA copy numbers
II	w	68	pT4, pN2 (17/31), Mx	
III	w	60	pT2a, pN2 (3/16), Mx	
IV	w	59	pT2a, pN0 (0/26), Mx	
IX	m	66	pT1a, pN0 (0/22), Mx	
V	w	68	pT2a, pN0 (0/19), Mx	
VI	m	60	pT2b, pN1 (4/38), Mx	
VII	w	66	pT2a, pN1 (6/30), Mx	
VIII	m	70	pT1ami, pN0 (0/31), Mx	
X	w	54	pT3, pN2 (1/ 17), Mx	
XI	m	74	pT3, pN0 (0/32), Mx	
XII	m	63	pT2a, pN0 (0/ 39), Mx	
XIII	m	81	pT2b, pN2 (5/49), Mx	
XIV	m	63	pT3, pN2 (7/35), Mx	
XV	m	57	pT3, pN0 (0/25), Mx	
XVI	m	66	pT3, pN1 (1/48), Mx	